Legalización del consumo de cannabis recreativo en adultos y problemas de salud mentales

Autores/as

DOI:

https://doi.org/10.30827/ars.v64i4.28681

Palabras clave:

Uso de la Marihuana, Cannabis, Políticas, Planificación y Administración en Salud, Salud mental, Educación para la salud

Resumen

Los problemas de salud mental hacen parte de las enfermedades no trasmisibles y se les atribuye, con otras enfermedades asociados al bienestar, hasta un 21 % de las muertes mundiales. Por ello, es necesario analizar y establecer la relación riesgo/beneficio de políticas relacionadas con la salud mental, caso de la legalización del consumo de cannabis recreativo en adultos. El cannabis es la droga “ilícita” de mayor consumo en los países occidentales, en esencia por incrementar la sociabilidad y la euforia. En la última década, varios países han promulgado normas orientadas a legalizar la comercialización de cannabis recreativo en adultos. En este sentido, existe controversia del efecto de este tipo de iniciativas, en el porcentaje de personas que consumen esta sustancia y en la salud de los mismos. Sin embargo, se podría esperar que este tipo de iniciativas favorezca un aumento en el porcentaje de personas que consumen esta sustancia. El aumento del consumo de marihuana puede favorecer una mayor prevalencia de problemas de salud mental, incluyendo psicosis y esquizofrenia. Se acepta la existencia de una asociación entre consumo de cannabis y psicosis (incluyendo esquizofrenia). En este marco, reconociendo los beneficios de las políticas de legalización del consumo de cannabis recreativo en adultos, orientadas a superar el enfoque prohibicionista y a buscar la reducción del daño, es conveniente evaluar y definir el efecto de las mismas. Además, estas iniciativas se deben acompañar de programas informativos y educativos, orientados a sintetizar los riesgos del consumo, incluyendo, la dependencia y problemas de salud mentales.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

World Health Organization. WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care. World Health Organization; Geneva, Switzerland: 2020.

Bonini SA, Premoli M, Tambaro S, et al. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018;227:300-315. doi: 10.1016/j.jep.2018.09.004.

Page RL 2nd, Allen LA, Kloner RA, et al; American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research. Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2020;142(10):e131-e152. doi: 10.1161/CIR.0000000000000883.

Gottschling S, Ayonrinde O, Bhaskar A, et al. Safety Considerations in Cannabinoid-Based Medicine. Int J Gen Med. 2020;13:1317-1333. doi: 10.2147/IJGM.S275049.

Sordo L, Gual A. Cannabis recreativo y cannabinoides terapéuticos, ni mezclados ni agitados [Recreational cannabis and therapeutic cannabinoids, neither shaken nor stirred]. Gac Sanit. 2022;36(6):500-501. doi: 10.1016/j.gaceta.2022.03.009.

Cohen K, Weizman A, Weinstein A. Positive and Negative Effects of Cannabis and Cannabinoids on Health. Clin Pharmacol Ther. 2019;105(5):1139-1147. doi: 10.1002/cpt.1381.

Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: Therapeutic Use in Clinical Practice. Int J Mol Sci. 2022;23(6):3344. doi: 10.3390/ijms23063344.

Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. Int J Mol Sci. 2021;22(17):9472. doi: 10.3390/ijms22179472.

Farrelly KN, Wardell JD, Marsden E, et al. The Impact of Recreational Cannabis Legalization on Cannabis Use and Associated Outcomes: A Systematic Review. Subst Abuse. 2023;17:11782218231172054. doi: 10.1177/11782218231172054

O’Grady MA, Iverson MG, Suleiman AO, Rhee TG. Is legalization of recreational cannabis associated with levels of use and cannabis use disorder among youth in the United States? A rapid systematic review. Eur Child Adolesc Psychiatry. 2022. doi: 10.1007/s00787-022-01994-9

Chiu V, Leung J, Hall W, Stjepanović D, Degenhardt L. Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA. Neuropharmacology. 2021;193:108610. doi: 10.1016/j.neuropharm.2021.108610

Freisthler B, Gruenewald PJ. Examining the relationship between the physical availability of medical marijuana and marijuana use across fifty California cities. Drug Alcohol Depend. 2014;143:244-50. doi: 10.1016/j.drugalcdep.2014.07.036

O’Hara SE, Paschall MJ, Grube JW. Recreational Marijuana Legalization, Local Retail Availability, and Alcohol and Marijuana Use and Co-Use among California High School Students. J Stud Alcohol Drugs. 2023. doi: 10.15288/jsad.22-00277

Paschall MJ, García-Ramírez G, Grube JW. Recreational Marijuana Legalization and Co-use With Alcohol Among Adolescents. Am J Prev Med. 2022;62:57-64. doi: 10.1016/j.amepre.2021.06.003

Leung J, Chan CJK, Hides L, Hall WD. What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. Addictive Behaviors. 2020;109:106479

Robinson T, Ali MU, Easterbrook B, et al. Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: A systematic review and meta-analysis. Drug Alcohol Depend. 2022;238:109582. doi: 10.1016/j.drugalcdep.2022.109582.

Johnson EC, Hatoum AS, Deak JD, et al. The relationship between cannabis and schizophrenia: a genetically informed perspective. Addiction. 2021;116(11):3227-3234. doi: 10.1111/add.15534

Lowe DJE, Sasiadek JD, Coles AS, George TP. Cannabis and mental illness: a review. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):107-120. doi: 10.1007/s00406-018-0970-7

Jefsen OH, Erlangsen A, Nordentoft M, Hjorthøj C. Cannabis Use Disorder and Subsequent Risk of Psychotic and Nonpsychotic Unipolar Depression and Bipolar Disorder. JAMA Psychiatry. 2023:e231256. doi: 10.1001/jamapsychiatry.2023.1256.

Urits I, Gress K, Charipova K, et al. Cannabis Use and its Association with Psychological Disorders. Psychopharmacol Bull. 2020;50(2):56-67.

Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull. 2016;42(5):1262-9. doi: 10.1093/schbul/sbw003.

Hasan A, von Keller R, Friemel CM, et al. Cannabis use and psychosis: a review of reviews. Eur Arch Psychiatry Clin Neurosci. 2020;270(4):403-412. doi: 10.1007/s00406-019-01068-z

Kiburi SK, Molebatsi K, Ntlantsana V, Lynskey MT. Cannabis use in adolescence and risk of psychosis: Are there factors that moderate this relationship? A systematic review and meta-analysis. Subst Abus. 2021;42(4):527-542. doi: 10.1080/08897077.2021.1876200.

Onaemo VN, Fawehinmi TO, D’Arcy C. Comorbid Cannabis Use Disorder with Major Depression and Generalized Anxiety Disorder: A Systematic Review with Meta-analysis of Nationally Representative Epidemiological Surveys. J Affect Disord. 2021;281:467-475. doi: 10.1016/j.jad.2020.12.043.

Solmi M, Radua J, Olivola M, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry. 2022;27:281-295. doi: 10.1038/s41380-021-01161-7

Ganesh S, D’Souza DC. Cannabis and Psychosis: Recent Epidemiological Findings Continuing the “Causality Debate”. Am J Psychiatry. 2022;179(1):8-10. doi: 10.1176/appi.ajp.2021.21111126

Hjorthøj C, Compton W, Starzer M, et al. Association between cannabis use disorder and schizophrenia stronger in young males than in females. Psychol Med. 2023:1-7. doi: 10.1017/S0033291723000880

Godin SL, Shehata S. Adolescent cannabis use and later development of schizophrenia: An updated systematic review of longitudinal studies. J Clin Psychol. 2022;78(7):1331-1340. doi: 10.1002/jclp.23312.

Global Initiative for Chronic Obstructive Lung Disease. Strategy Report 2023. Disponible en: https://goldcopd.org/

Tan WC, Bourbeau J, Aaron SD, et al; CanCOLD Collaborative Research Group; Members of the CanCOLD Collaborative Research Group not listed as authors. The effects of marijuana smoking on lung function in older people. Eur Respir J. 2019;54(6):1900826. doi: 10.1183/13993003.00826-2019.

Malinowska-Sempruch K, Lohman D. From drug prohibition to regulation: a public health imperative. Lancet. 2022;400(10353):645-646. doi: 10.1016/S0140-6736(22)01060-1.

Mundt AP, Ibáñez C. Beyond the dichotomy of drug regulations and prohibitions. Lancet. 2023;401(10388):1567. doi: 10.1016/S0140-6736(23)00552-4.

Shover CL, Humphreys K. Six policy lessons relevant to cannabis legalization. Am J Drug Alcohol Abuse. 2019;45(6):698-706. doi: 10.1080/00952990.2019.1569669.

Descargas

Publicado

2023-09-22

Cómo citar

1.
Amariles P. Legalización del consumo de cannabis recreativo en adultos y problemas de salud mentales. Ars Pharm [Internet]. 22 de septiembre de 2023 [citado 23 de febrero de 2024];64(4):348-5. Disponible en: https://revistaseug.ugr.es/index.php/ars/article/view/28681

Número

Sección

Artículos especiales